Physician profile
Daniel Bruce Thistlethwaite
NPI 1518083328
$467,514.72
in general payments reported to CMS, 2019-2025
32 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $11K · 2021: $22K · 2022: $39K · 2023: $100K · 2024: $122K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250K · Consulting Fee: $43K · Honoraria: $29K · Travel and Lodging: $28K · Food and Beverage: $13K · Education: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $249,577.75 |
| Consulting Fee | $42,710.00 |
| Honoraria | $28,950.00 |
| Travel and Lodging | $27,814.09 |
| Food and Beverage | $13,081.75 |
| Education | $334.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $118,916.25 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $109,528.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $92,877.55 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $70,635.08 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $48,609.67 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Allergan, INC. | $10,388.27 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,730.48 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $1,468.46 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Harmony Biosciences LLC | $831.39 | 2020-2025 | Wakix |
| Lundbeck LLC | $804.29 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $579.69 | 2020-2025 | Caplyta |
| Brainsway USA INC | $535.76 | 2019-2021 | |
| Corium, LLC | $359.32 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $332.87 | 2019-2021 | |
| Tris Pharma INC | $299.35 | 2019-2025 | Dyanavel Xr, Quillichew Er |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $268.55 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $263.01 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $155.63 | 2019-2025 | Fanapt |
| Biogen, INC. | $125.92 | 2021-2022 | |
| Shire North American Group INC | $125.69 | 2019 | |
| Eisai INC. | $123.16 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $112.75 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $104.79 | 2019-2022 | |
| Neos Therapeutics, Lp | $82.06 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $67.97 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $47.32 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $35.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $29.58 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $27.06 | 2020 | |
| Indivior INC. | $19.99 | 2022 | |
| Almatica Pharma LLC | $16.59 | 2021 | |
| Aytu Biopharma, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Thistlethwaite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.